JeanMarie Guenot features an extensive portfolio with over two decades of experience. She has been in both the biotechnology and pharmaceutical sectors for a substantial period of time in which she has acquired relevant expertise. JeanMarie received her Ph.D. degree from the University of California in addition to a Wharton School’s MBA degree. Guenot has experiences in many fields as she has served in both private and public sectors. Noticeably, she has offered her expertise in various corporate, venture capital, alliance management, project management and pharmaceutical R & D activities.
Jean Marie has worked with various organizations in different capacities of leadership. She previously served at Hoffmann-La Roche in Shanghai and Basel where she offered her advisory services. Additionally, Guenot is a businessperson and the founder of a startup firm known as SKS Ocular. At the startup company, she served in varied departments such as release and delivery of ocular drugs, inflammation of ocular, glaucoma, and macular degeneration. Guenot has been the recipient of numerous awards and recognitions. In 2005, for instance, the Bio Network Award awarded her for innovation.
Presently, Guenot offers her services to Amphivena Therapeutics, where she serves as the president. During her presidency tenure, the firm has experienced unprecedented growth in the sector. The company specializes in conducting research and developing approaches to combating blood cancer. The company was instituted in 2013 and is headquartered in California’s San Francisco. Amphivena Therapeutics was founded to facilitate healthy living of patients of cancer patients.
Since its inception, the facility has accomplished substantial objectives in developing reliable strategies towards the cancer menace. The firm, through the leadership of JeanMarie Guenot, has managed to develop various therapies, which have been targeted at destroying cancerous cells. Through the adept capabilities of the vigorous and passionate woman that Guenot is, the facility had assisted a large number of cancer patients, who would have otherwise not survived without proper care. Amphivena
Therapeutics has collaborated with Janssen Biotech, a partnership that was successfully negotiated by JeanMarie Guenot herself. Janssen Biotech acknowledged the pleasant achievements of Amphivena Therapeutics and released substantial payments to the enterprise. With the successful leadership of Guenot, there is a high likelihood that the corporation will continue growing and excelling in the industry.